GISTs are the most common mesenchymal neoplasms of the gastrointestinal tract, and are characterized b the expression of activating mutations of KIT. Imatinib (Gleevec) induces objective responses and durable disease control in the majority of pts wit...
GISTs are the most common mesenchymal neoplasms of the gastrointestinal tract, and are characterized b the expression of activating mutations of KIT. Imatinib (Gleevec) induces objective responses and durable disease control in the majority of pts with metastatic GIST. However, the incidence of resistance to imatinib increases over time in these pts, necessitating the development of alternate strategies to control this disease.